A Cluster Randomised Trial Comparing the Impact of Immediate Versus WHO Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.

Trial Profile

A Cluster Randomised Trial Comparing the Impact of Immediate Versus WHO Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 Results assessing virological response and emergence of drug resistance, presented at the 9th International AIDS Society Conference on HIV Science.
    • 26 Jul 2017 Results of care trajectories and factor associated (n=787) presented at the 9th International AIDS Society Conference on HIV Science
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top